logo

ZTS

Zoetis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 5
Sell signal 1
dividend princes
consensus rating "Buy"
MACD Golden Cross
Revenue Beats Expectation
Low Beta
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About ZTS

Zoetis Inc.

A world's leading animal health medicines and vaccines developer with a focus on livestock and companion animals

Pharmaceutical
Invalid Date
02/01/2013
New York Stock Exchange
13800
12-31
Common stock
10 Sylvan Way, Parsippany, New Jersey 07054
Production and development of pet health drug products and vaccines
Zoetis, Inc. was founded in July 2012 in Delaware, USA. Zoetis is a global leader in the animal health industry, focusing on the discovery, development, manufacturing and commercialization of drugs, vaccines, diagnostic products and services, biological devices, genetic testing and precision animal health.

Company Financials

EPS

ZTS has released its 2024 Q4 earnings. EPS was reported at 1.40, versus the expected 1.34, beating expectations. The chart below visualizes how ZTS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ZTS has released its 2024 Q4 earnings report, with revenue of 2.32B, reflecting a YoY change of 4.70%, and net profit of 581.00M, showing a YoY change of 11.09%. The Sankey diagram below clearly presents ZTS’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime